Ainos, Inc. (AIMD)
| Market Cap | 7.87M |
| Revenue (ttm) | 20,729 |
| Net Income (ttm) | -14.86M |
| Shares Out | 15.43M |
| EPS (ttm) | -1.56 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 38,427 |
| Open | 0.5020 |
| Previous Close | 0.5200 |
| Day's Range | 0.5102 - 0.5200 |
| 52-Week Range | 0.4000 - 1.4600 |
| Beta | 1.52 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Mar 7, 2025 |
About AIMD
Ainos, Inc., a healthcare company, focuses on the development of novel point-of-care testing therapeutics based on very low-dose interferon alpha and synthetic RNA-driven preventative medicine. The company provides COVID-19 antigen rapid test kit and VELDONA pet supplement, a health issues in dogs and cats, including skin, gum, emotion, discomfort caused by allergies, eye, and weight-related issues. It offers VELDONA human and animal drugs, a human drug pipeline includes treatments for oral warts in HIV-seropositive patients, Sjögren’s syndrome... [Read more]
Financial Performance
In 2024, Ainos's revenue was $20,729, a decrease of -83.02% compared to the previous year's $122,112. Losses were -$14.86 million, 7.93% more than in 2023.
Financial StatementsNews
Ainos to Participate in Fireside Chat with Water Tower Research on April 8, 2025
SAN DIEGO, CALIFORNIA / ACCESS Newswire / March 24, 2025 / Ainos, Inc. (NASDAQ:AIMD)(NASDAQ:AIMDW) ("Ainos" or the "Company"), a leader in AI-powered scent digitization, today announced that it will p...
Water Tower Research Spotlights Ainos & ASE Partnership: Unleashing AI Nose's Potential in Chip Manufacturing and More
Another key win in expanding AI Nose's industrial opportunities Partnership to integrate AI Nose into ASE's factories and explore broader industrial use-cases SAN DIEGO, CALIFORNIA / ACCESS Newswire /...
Ainos and ASE Partner to Power AI Scent Digitization in Semiconductor Manufacturing
Harnessing AI-Powered Scent Digitization for Smarter, Safer, and More Sustainable Factories SAN DIEGO, CA / ACCESS Newswire / March 11, 2025 / Ainos, Inc. (NASDAQ:AIMD)(NASDAQ:AIMDW) ("Ainos" or the "...
Ainos Reports Full Year 2024 Financial Results
Unveiled revolutionary AI Nose for robotics application, inviting global robotics companies to join Ainos Alliance in shaping the future of smell-enabled robots Advanced VELDONA® development with key ...
Water Tower Research Highlights Ainos & ugo Partnership: The Final Sense for Robots - AI Smell is Here
Practical partnership for AI Nose, multiple new opportunities AI Nose to change robotics landscape with first AI smell sensing SAN DIEGO, CA / ACCESS Newswire / March 7, 2025 / Ainos, Inc. (NASDAQ:AIM...
Ainos and ugo to Develop the World's First Robot With a Sense of Smell
A Major Breakthrough in Ainos' Mission to Digitize Scent First-ever Smell-Enabled Robotics Will Unlock New Revenue Streams in Smart Manufacturing, Public Safety and more SAN DIEGO, CA / ACCESS Newswir...
Ainos Achieves Major Breakthrough: Japan Patent Approval for VELDONA Redefines Antiviral Innovation
Revolutionary Oral Interferon Technology Combines Unmatched Advantages and Global Potential in the $16 Billion Coronavirus Market SAN DIEGO, CA / ACCESS Newswire / January 27, 2025 / Ainos, Inc. (NASD...
Water Tower Research Spotlights Ainos' AI Nose Programs and Strategic Milestones for 2025
SAN DIEGO, CA / ACCESS Newswire / January 21, 2025 / Ainos, Inc. (NASDAQ:AIMD)(NASDAQ:AIMDW) ("Ainos" or the "Company"), a pioneer of digiting scent and low-dose interferon therapeutics, today announc...
Ainos Granted 180-Day Extension by Nasdaq to Regain Compliance With Minimum Bid Price Rule
SAN DIEGO, CA / ACCESS Newswire / January 17, 2025 / Ainos, Inc. (NASDAQ:AIMD)(NASDAQ:AIMDW) ("Ainos", or the "Company"), today announced that it had received written notification (the "Written Notifi...
Ainos Unveils AI Nose for Robotics: Invites Global Robotics Companies to Join Forces in Shaping the Future of Smell-Enabled Robots
Ainos, Inc. (NASDAQ:AIMD)(NASDAQ:AIMDW), a pioneer of digitizing scent, proudly announces its revolutionary AI Nose for robotics application and invites robotics companies worldwide to join Ainos Alli...
CORRECTION BY SOURCE: Smell the Future: Ainos Elevates Health and Technology With AI Nose and VELDONA
The following CORRECTS and REPLACES the release that was issued earlier today: Updated partner for VOC detection platform development From giving AI the sense of smell and breakthrough in rare disease...
Smell the Future: Ainos Elevates Health and Technology With AI Nose and VELDONA
From giving AI the sense of smell and breakthrough in rare disease treatments, Ainos is shaping 2025 with bold technologies and strategic collaborations SAN DIEGO, CA / ACCESSWIRE / December 18, 2024 ...
Ainos Joins Webull Corporate Connect Service Platform to Enhance Investor Engagement
SAN DIEGO, CA / ACCESSWIRE / December 13, 2024 / Ainos, Inc. (NASDAQ:AIMD)(NASDAQ:AIMDW) ("Ainos" or the "Company"), an innovative healthcare company focused on advanced AI-driven point-of-care testin...
Water Tower Research Underscores Ainos' Partnership With Taiwan Tanabe Seiyaku for VELDONA Manufacturing and Marketing
SAN DIEGO, CA / ACCESSWIRE / December 4, 2024 / Ainos, Inc. (NASDAQ:AIMD)(NASDAQ:AIMDW) ("Ainos" or the "Company"), an innovative healthcare company focused on advanced AI-driven point-of-care testing...
Ainos, Inc. Announces Strategic Partnership with Taiwan Tanabe Seiyaku to Advance Manufacturing and Taiwan Market Promotion of Sjögren's Syndrome Drug
San Diego, California--(Newsfile Corp. - December 2, 2024) - Ainos, Inc. (NASDAQ: AIMD) (NASDAQ: AIMDW) ("Ainos" or the "Company"), an innovative healthcare company focused on advanced AI-driven point...
Water Tower Research Highlights IRB Approval for the Ainos VELDONA Clinical Sjogren's Trial Alongside 3Q24 Earnings and Developments
Taiwan regulatory approval for the trial expected in Q1 2025 Remains committed to a capital-efficient business strategy SAN DIEGO, CA / ACCESSWIRE / November 13, 2024 / Ainos, Inc. (NASDAQ:AIMD)(NASDA...
Ainos Announces IRB Approval for Sjögren's Syndrome Clinical Study at Shuang Ho Hospital, Affiliated with Taipei Medical University, and Plans to Initiate New Phase of Treatment Evaluation in Q1 2025
IRB approval on track as scheduled Next step is obtaining all regulatory approvals, followed by site initiation visit VELDONA significantly increases unstimulated whole salivary flow in prior Phase 3 ...
Ainos Takes Decisive Action to Protect Stockholder Interests and Combat Potential Illegal Trading Activities
SAN DIEGO, CA / ACCESSWIRE / November 8, 2024 / Ainos, Inc. (NASDAQ:AIMD)(NASDAQ:AIMDW) ("Ainos" or the "Company"), an innovative healthcare company focused on advanced AI-powered point-of-care testin...
Ainos Reports Third Quarter 2024 Financial Results
Secured multi-regional patent assets, strengthening Ainos' AI Nose technology. Expanded VELDONA® patent portfolio with a new invention patent for treatments and preventions for coronavirus infections.
Ainos Expands Patent Portfolio With Strategic Shareholder's Cutting-Edge Technology Assets
Strengthens AI Nose Gas Sensing Technology with Additional Exclusively Licensed Patents Secures Exclusive Rights to Breakthrough Nitrogen-Oxygen Separation Technology with Superior Energy Efficiency a...
Ainos Highlights VELDONA Clinical Advancements and Market Potential in Water Tower Research Spotlight Podcast
Prioritizing VELDONA®'s development for oral warts in HIV+ patients and Sjogren's syndrome Burgeoning pet care market also presents growth opportunities for VELDONA® SAN DIEGO, CA / ACCESSWIRE / Octob...
Ainos Advances Healthcare and Industrial Innovations with AI Nose and VELDONA Technologies
Ainos pioneers AI-powered digital nose technology with VOC detection breakthroughs for early disease diagnosis, industrial safety, and human-like sensory capabilities in robots VELDONA® low-dose oral ...
Ainos, Inc. Receives IRB Approval From National Taiwan University Hospital for HIV-Oral Warts Clinical Trial, Highlighting Value of FDA-Designated Orphan Drug VELDONA
Next step will be receiving approval from Taiwan Food and Drug Administration (TFDA) SAN DIEGO, CA / ACCESSWIRE / September 25, 2024 / Ainos, Inc. (NASDAQ:AIMD)(NASDAQ:AIMDW) ("Ainos" or the "Company"...
Ainos Spotlighted in Water Tower Research Report on VELDONA Clinical Study for Sjogren's Syndrome
Sjogren's Syndrome is a rare autoimmune disease with limited treatment options Prior U.S. Phase 3 data demonstrated benefits SAN DIEGO, CA / ACCESSWIRE / September 24, 2024 / Ainos, Inc. (NASDAQ:AIMD)...
Ainos Announced Plan to Initiate Taiwan Clinical Study of VELDONA for Treating Sjögren's Syndrome, a Rare Disease With Limited Treatment Options
Prior Phase 3 studies showed positive benefits in increasing unstimulated whole saliva secretion Ainos aims to complete all regulatory approvals for the study in Q4 2024 SAN DIEGO, CA / ACCESSWIRE / S...